Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,594 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A stealth antigen SPESP1, which is epigenetically silenced in tumors, is a suitable target for cancer immunotherapy.
Kosaka A, Yajima Y, Hatayama M, Ikuta K, Sasaki T, Hirai N, Yasuda S, Nagata M, Hayashi R, Harabuchi S, Ohara K, Ohara M, Kumai T, Ishibashi K, Hirata-Nozaki Y, Nagato T, Oikawa K, Harabuchi Y, Celis E, Okumura T, Ohsaki Y, Kobayashi H, Ohkuri T. Kosaka A, et al. Among authors: ohara m, ohara k. Cancer Sci. 2021 Jul;112(7):2705-2713. doi: 10.1111/cas.14973. Epub 2021 Jun 3. Cancer Sci. 2021. PMID: 34009705 Free PMC article.
Recent changes in nasopharyngeal flora of children in Japan.
Hayashi T, Yoshizaki T, Ohara K, Yoshida S, Kumai T, Harabuchi Y. Hayashi T, et al. Among authors: ohara k. Adv Otorhinolaryngol. 2011;72:176-8. doi: 10.1159/000324789. Epub 2011 Aug 18. Adv Otorhinolaryngol. 2011. PMID: 21865722
Clinical images: Eagle's syndrome.
Nagato T, Ohara K, Takahara M, Hayashi T, Harabuchi Y. Nagato T, et al. Among authors: ohara k. Arthritis Rheum. 2012 May;64(5):1561. doi: 10.1002/art.34418. Arthritis Rheum. 2012. PMID: 22307685 Free article. No abstract available.
Epigenetic modification augments the immunogenicity of human leukocyte antigen G serving as a tumor antigen for T cell-based immunotherapy.
Ishibashi K, Kumai T, Ohkuri T, Kosaka A, Nagato T, Hirata Y, Ohara K, Oikawa K, Aoki N, Akiyama N, Sado M, Kitada M, Harabuchi Y, Celis E, Kobayashi H. Ishibashi K, et al. Among authors: ohara k. Oncoimmunology. 2016 Mar 30;5(6):e1169356. doi: 10.1080/2162402X.2016.1169356. eCollection 2016 Jun. Oncoimmunology. 2016. PMID: 27471649 Free PMC article.
Intratumoral administration of cGAMP transiently accumulates potent macrophages for anti-tumor immunity at a mouse tumor site.
Ohkuri T, Kosaka A, Ishibashi K, Kumai T, Hirata Y, Ohara K, Nagato T, Oikawa K, Aoki N, Harabuchi Y, Celis E, Kobayashi H. Ohkuri T, et al. Among authors: ohara k. Cancer Immunol Immunother. 2017 Jun;66(6):705-716. doi: 10.1007/s00262-017-1975-1. Epub 2017 Feb 27. Cancer Immunol Immunother. 2017. PMID: 28243692 Free PMC article.
Programmed death-ligand 1 and its soluble form are highly expressed in nasal natural killer/T-cell lymphoma: a potential rationale for immunotherapy.
Nagato T, Ohkuri T, Ohara K, Hirata Y, Kishibe K, Komabayashi Y, Ueda S, Takahara M, Kumai T, Ishibashi K, Kosaka A, Aoki N, Oikawa K, Uno Y, Akiyama N, Sado M, Takei H, Celis E, Harabuchi Y, Kobayashi H. Nagato T, et al. Among authors: ohara k. Cancer Immunol Immunother. 2017 Jul;66(7):877-890. doi: 10.1007/s00262-017-1987-x. Epub 2017 Mar 27. Cancer Immunol Immunother. 2017. PMID: 28349165 Free PMC article.
Intratumoral injection of IFN-β induces chemokine production in melanoma and augments the therapeutic efficacy of anti-PD-L1 mAb.
Uehara J, Ohkuri T, Kosaka A, Ishibashi K, Hirata Y, Ohara K, Nagato T, Oikawa K, Aoki N, Harabuchi Y, Ishida-Yamamoto A, Kobayashi H. Uehara J, et al. Among authors: ohara k. Biochem Biophys Res Commun. 2017 Aug 19;490(2):521-527. doi: 10.1016/j.bbrc.2017.06.072. Epub 2017 Jun 15. Biochem Biophys Res Commun. 2017. PMID: 28624449
Targeting phosphorylated p53 to elicit tumor-reactive T helper responses against head and neck squamous cell carcinoma.
Ohara K, Ohkuri T, Kumai T, Nagato T, Nozaki Y, Ishibashi K, Kosaka A, Nagata M, Harabuchi S, Ohara M, Oikawa K, Aoki N, Harabuchi Y, Celis E, Kobayashi H. Ohara K, et al. Among authors: ohara m. Oncoimmunology. 2018 Aug 1;7(9):e1466771. doi: 10.1080/2162402X.2018.1466771. eCollection 2018. Oncoimmunology. 2018. PMID: 30510853 Free PMC article.
Cyclin-dependent kinase 1 and survivin as potential therapeutic targets against nasal natural killer/T-cell lymphoma.
Nagato T, Ueda S, Takahara M, Kishibe K, Komabayashi Y, Kumai T, Ohara K, Hirata-Nozaki Y, Harabuchi S, Hayashi R, Ohkuri T, Bernasconi M, Nadal D, Kobayashi H, Harabuchi Y. Nagato T, et al. Among authors: ohara k. Lab Invest. 2019 May;99(5):612-624. doi: 10.1038/s41374-018-0182-9. Epub 2019 Jan 21. Lab Invest. 2019. PMID: 30664711 Free article.
PD-L1-specific helper T-cells exhibit effective antitumor responses: new strategy of cancer immunotherapy targeting PD-L1 in head and neck squamous cell carcinoma.
Hirata-Nozaki Y, Ohkuri T, Ohara K, Kumai T, Nagata M, Harabuchi S, Kosaka A, Nagato T, Ishibashi K, Oikawa K, Aoki N, Ohara M, Harabuchi Y, Uno Y, Takei H, Celis E, Kobayashi H. Hirata-Nozaki Y, et al. Among authors: ohara m, ohara k. J Transl Med. 2019 Jun 20;17(1):207. doi: 10.1186/s12967-019-1957-5. J Transl Med. 2019. PMID: 31221178 Free PMC article.
1,594 results